Author
Paul Pollack 1
1 Eli Lilly and Company, Indianapolis, United States
EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE
Geert R. D'Haens, Stefan Schreiber, Edouard Louis, Bruce E. Sands, Elisa Gomez Valderas, Debra Miller, Noah Agada, April Naegeli, Paul Pollack, Jochen Schmitz, Janneke van der Woude, Jaroslaw Kierkuś, William Sandborn